Connect with us

Health

PROSTATE CANCER FOUNDATION-FUNDED GENETIC STUDY OF MEN OF AFRICAN ANCESTRY FINDS NEW RISK FACTORS FOR PROSTATE CANCER

Published

on

The largest-ever genetic study of prostate cancer in Black men identified nine new gene variants that increase risk, determined polygenic risk score can predict more aggressive disease.

LOS ANGELES, March 3, 2023 /PRNewswire/ — One in six Black men in the United States will be diagnosed with prostate cancer in his lifetime versus one in eight white men. Black men are more likely to be diagnosed at a younger age, with more aggressive disease, and are more than twice as likely to die of prostate cancer. New findings from Prostate Cancer Foundation (PCF)-funded investigators shed light on the genetic underpinnings of this racial disparity and point the way toward more effective screening strategies.

Studies have identified close to 270 genetic variants linked to prostate cancer risk, but genetic researchers have yet to explain the disproportionate risk among men of African ancestry. Nor have they been able to predict which Black men face a high risk for aggressive prostate cancer.

To address these questions, Christopher Haiman, ScD, director of the Center for Genetic Epidemiology at the Keck School of Medicine of USC and AFLAC Chair of Cancer Research at the USC Norris Comprehensive Cancer Center, led a meta-analysis of 10 genome-wide association studies pooling data representing more than 80,000 men of African ancestry (19,378 men with prostate cancer and 61,620 healthy controls) collected in the U.S., Africa and the Caribbean.

The researchers found nine previously undiscovered genetic variants that increased the risk for prostate cancer in men of African ancestry, seven of which are found either largely or exclusively in Black men. One new variant in the 8q24 region, long known to influence prostate cancer risk, is found only in men of African ancestry. This variant influences the risk of higher rates of aggressive disease among Black men, researchers concluded. They also showed that a multiancestry polygenic risk score was able to differentiate between the risks of developing aggressive and nonaggressive prostate cancer in men of African ancestry. Their study was published March 3 in the peer reviewed journal European Urology.

The newly identified variants can be used to refine polygenic risk scores, genetic tests that assess a person’s risk for developing a condition based on the combined influence of multiple genetic factors and can help patients decide how early and often to get screened.

“Addressing African American disparity in prostate cancer is a critical focus for the Prostate Cancer Foundation and we congratulate Dr. Haiman and colleagues on their findings which will lead to more effective precision screening strategies for men of African ancestry,” said PCF President and CEO Charles J. Ryan, MD. “Through the Robert F. Smith-PCF Special Challenge Award for the Smith Polygenic Risk Test, we are proud to invest in the vital work of Dr. Haiman and all of the RESPOND investigators to understand and address the reasons why Black men disproportionately experience aggressive prostate cancer.”

Haiman and collaborators study prostate cancer among Black men through the $26.5 million, multi-center RESPOND (Research on Prostate Cancer in African American Men: Defining the Roles of Genetics, Tumor Markers and Social Stress) study, funded by the PCF, the National Cancer Institute, and the National Institute on Minority Health and Health Disparities. This work is ongoing, including research into how social determinants, access to care, genetics, and tumor characteristics affect prostate cancer diagnosis, progression, recurrence and survival rates.

With funding support from PCF and Robert F. Smith, Haiman and colleagues also are working to develop the Smith Polygenic Risk Test for Prostate Cancer, a non-invasive, early detection test that will identify a man’s lifetime prostate cancer risk using a combination of the nearly 270 genetic variants obtained from a single sample of saliva or blood.

“The results of this research will markedly change the ways physicians test for prostate cancer. We now have the ability to identify at-risk men before they develop the disease and proactively implement the most effective preventive measures and treatments,” said Robert F. Smith, Founder, Chairman and CEO of Vista Equity Partners. “We must continue to make investments in health equity research and transform prostate cancer from a life-altering diagnosis into a manageable condition.”

Advertisement
Get More From A Face Cleanser And Spa-like Massage

Since its founding in 1993, PCF has invested over $30 million in health disparities research through 48 different research programs with more than 20 institutional collaborators.

About the Prostate Cancer Foundation
The Prostate Cancer Foundation (PCF) is the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research. Founded in 1993 by Mike Milken, PCF has been responsible for raising close to $1 billion in support of cutting-edge research by more than 2,250 research projects at 245 leading cancer centers in 28 countries around the world. Since PCF’s inception, and through its efforts, patients around the world are living longer, suffering fewer complications, and enjoying better quality of life. PCF is committed to creating a global public square for prostate cancer, in service to our mission of ending death and suffering from the disease. Learn more at pcf.org.

SOURCE Prostate Cancer Foundationmt

health and wellness

How Clinical Trials Really Work: Understanding the 4 Phases

Understanding how clinical trials work can help demystify the experience, while the research itself helps answer important questions about diseases, treatment options and more. If you, your healthcare team and the study researchers decide an experimental drug trial is right for you, different questions will be answered depending on which phase you participate in.

Published

on

How Clinical Trials Really Work: Understanding the 4 Phases

How Clinical Trials Really Work: Understanding the 4 Phases

(Feature Impact) The idea of participating in a clinical trial can feel overwhelming, especially if you aren’t sure what’s actually involved in the process. Understanding how clinical trials work can help demystify the experience, while the research itself helps answer important questions about diseases, treatment options and more.

According to a study by the Crohn’s & Colitis Foundation, nearly 1 in 100 Americans has inflammatory bowel disease (IBD), a term encompassing a group of conditions that includes Crohn’s disease and ulcerative colitis. These disorders affect the gastrointestinal tract and cause inflammation of the intestines, which can lead to symptoms and sometimes more complicated issues throughout the body. Research into this condition has the potential to change lives, including those of the participants themselves, yet many clinical trials face delays due to lack of enrollment.

“We need more people to get involved in clinical trials, especially those from underrepresented communities, including people of color and older adults, who have some of the highest rates of chronic disease,” said Dr. Ruby Greywoode, a gastroenterologist at Montefiore Medical Center.

Clinical trials can take many forms including medication studies, medical tests, investigating the role of diet in disease management or examining the emotional impact of living with a condition such as IBD. Each trial is typically divided into four phases, which all build on each other but are conducted separately.

If you, your healthcare team and the study researchers decide an experimental drug trial is right for you, different questions will be answered depending on which phase you participate in.

Phase 1: Is the Drug Safe to Use?

The first phase of a clinical trial is the smallest and often conducted among a group of healthy people who don’t have the condition in question. Researchers want to know how the human body reacts to the medication, determine safe dosage ranges and identify potential side effects.

Phase 2: Is the Drug Effective?

Once a drug has been evaluated for overall safety in healthy people, the clinical trial moves on to test the treatment in a slightly larger group of people. Those participating in this phase have the condition for which the new treatment is being developed. For instance, a phase 2 IBD clinical trial might give the drug to 100 people with IBD to see whether it works or causes any short-term side effects. Participants are randomly assigned to different treatment groups, which may involve different dosages or placebos (not active treatment).

18243 detail embed2Phase 3: Does It Work Better Than Currently Available Treatments?

If the second phase yields positive results, the study expands again to test the new drug against current treatment options. A phase 3 clinical trial lasts longer and involves more participants than the first two phases as researchers try to gain as much information as possible about how the drug affects different kinds of people, whether it’s better than standard treatments or placebos and what side effects may arise over a longer period of time.

At the end of this phase, the company decides whether the trial results are strong enough to submit an application to the FDA, at which point the treatment will be reviewed and potentially approved.

Phase 4: How Does the Drug Work in Real Life?

Research usually doesn’t end when a drug gets approved. Instead, it moves into the fourth phase, where companies monitor the ongoing real-world uses and effects of the medication. This can involve following thousands of patients for several years to gather as much information as possible.

If you’re one of the millions of people living with IBD in the U.S., clinical trials offer hope for a future with more treatments, less pain and healthier lives. That’s why the Crohn’s & Colitis Foundation wants to make clinical trials less mysterious, more accessible and more representative of the real people affected by these conditions.

Advertisement
Get More From A Face Cleanser And Spa-like Massage

Talk to your healthcare professional about whether a clinical trial could be right for you and explore IBD research opportunities at CrohnsColitisFoundation.org.

Clinical Trial FAQs

What is the average length of a clinical trial?

The length of clinical trials vary. They can be as short as a month or as long as one year or more. Generally, the earlier the phase, the shorter the trial period. How do you identify clinical trials you’re eligible for?

Eligibility criteria differ from study to study and may include factors like age, gender, medical history and current health status. For instance, some IBD studies may be looking for patients with mild symptoms, while others want to test treatments for moderate to severe disease. If you’re interested in a particular trial, review the criteria to see if you qualify to participate.

Is it free to participate in clinical trials?

Most clinical trials are federally or privately funded, so there is typically no cost to the participant. Associated costs like travel, time off work and childcare may or may not be covered by the trial sponsor, so it’s worth confirming these details before committing.

What if you enroll in a trial then change your mind?

You’re free to withdraw from a clinical trial at any time. If you drop out during testing, you may be asked to come in for follow-up visits to ensure your safety.

If the treatment helps, can you keep using it after the trial ends?

It depends. Some trial sponsors allow participants to continue receiving the drug voluntarily, while others only make it available after it’s been approved by the FDA.

How can you get involved in clinical trials?

Talk to your doctor about whether participating in a clinical trial may be right for you. If you’re interested in IBD clinical trials, you and your doctor can search for opportunities at crohnscolitisfoundation.org/clinical-trials-community.

“Clinical trials give patients a real way to shape the future of treatment,” Greywoode said. “It’s not just about their own care; it can help others, too. Talking openly with your doctor can help you feel more confident about getting involved.”

Photos courtesy of Shutterstock

collect?v=1&tid=UA 482330 7&cid=1955551e 1975 5e52 0cdb 8516071094cd&sc=start&t=pageview&dl=http%3A%2F%2Ftrack.familyfeatures
track

SOURCE:

Crohn’s & Colitis Foundation

Advertisement
Get More From A Face Cleanser And Spa-like Massage
https://stmdailynews.com/menopause-changes-your-mouth-most-women-have-no-idea/
Continue Reading

Health

Radon is the second leading cause of lung cancer. 8 in 10 US adults have never tested their home for it

Decades of public health campaigns have reinforced the connection between smoking and lung cancer, helping people understand that their choices can influence their health. Despite radon being the second-leading cause of lung cancer, many have never tested their home for it.

Published

on

Radon is the second leading cause of lung cancer. 8 in 10 US adults have never tested their home for it

Radon is the second leading cause of lung cancer. 8 in 10 US adults have never tested their home for it

(Sheeka Sanahori) Avoid tobacco products. Eat a healthy diet. Get recommended cancer screenings. Most U.S. adults recognize these behaviors as ways to lower their cancer risk or catch cancer early. Decades of public health campaigns have reinforced the connection between smoking and lung cancer, helping people understand that their choices can influence their health.

But U.S. adults are far less likely to recognize a risk factor they can’t control through daily habits. Radon – an odorless, invisible gas that forms naturally in the ground – is the second leading cause of lung cancer, but new research from the Prevent Cancer Foundation finds that 8 in 10 U.S. adults have never tested their home for radon. The findings are based on the Foundation’s annual Early Detection Survey of more than 7,000 U.S. adults, conducted in January 2026.

With recent high-profile lung cancer cases, such as the October diagnosis of Pope Leo XIV, who is not known to have a history of smoking cigarettes, more people are paying attention to other risk factors for lung cancer, especially for people who have never smoked.

18265 B detail embed2

Testing for radon is last on the list

When asked about preventive behaviors, 77.5% say avoiding tobacco lowers their cancer risk. Three out of four say eating a healthy diet and getting routine cancer screenings make a difference, too. More than half also named regular exercise, limiting alcohol and protecting themselves from harmful UV rays.

Testing their home for radon ranked last on the list of preventive behaviors, with only 28% listing it as a way to reduce their cancer risk.

18265 C detail embed3

Most homes go untested in every region

Radon hasn’t reached the same level of public awareness as tobacco use, diet and exercise. U.S. adults appear to overlook an environmental risk that could be inside their own homes. Eighty percent of U.S. adults report never having their homes tested for radon, and only 12% have tested within the last five years. The U.S. Environmental Protection Agency (EPA) recommends testing every two years.

In the Northeast, about 7 in 10 people (72%) have never tested their home for radon. That percentage increases for the Midwest (79%), West (82%) and South (83%). Unlike cigarettes, radon does not produce smoke and is odorless, so a test is the only way to detect its presence.

18265 D detail embed4

What it takes to find out

Radon can enter homes through the ground when uranium underneath decays. Once it’s inside, it gets trapped. People can live with high radon levels without knowing it, in older homes and new construction alike. Breaking ground on undisturbed land during construction can release more radon.

Renters can either test themselves or ask their landlord whether the home has been tested and request the results. Landlord requirements vary by state.

Test kits are inexpensive and available online and at home improvement stores. The EPA recommends taking action to reduce radon levels at 4 picocuries per liter (pCi/L) or higher, and notes that levels below that may still carry risk. If levels are high, a mitigation system can bring them down.

Beyond radon, the EPA and other health authorities cite avoiding tobacco and secondhand smoke as the most significant steps people can take to lower lung cancer risk, along with following screening guidelines based on personal risk factors.

Methodology

The Prevent Cancer Foundation commissioned Atomik Research to conduct the Foundation’s fourth annual Early Detection Survey of U.S. adults. The study consists of an online survey questionnaire, which includes several repeated measures from a previous year’s questionnaire and a primary data set gathered from a sample of 7,510 adults located throughout the United States. The sample consists of adults 21 years of age or older, and researchers implemented several demographic-based quotas in order to achieve sample characteristics similar to the overall U.S. population of adults 21 and older.

Researchers controlled for demographic variables such as biological sex, age group classification, race/ethnicity, parental status, geographic region, employment status and community classifications (e.g., urban or rural classification).

Advertisement
Get More From A Face Cleanser And Spa-like Massage

The margin of error of the overall sample is +/-1 percentage point with a confidence level of 95%. Fieldwork took place between Jan. 10 and Jan. 30, 2026. Atomik Research is an independent market research agency.

Percentages may not add up to 100% due to computer rounding, and/or the acceptance of multiple responses.

Photo courtesy of Shutterstock (family playing)

collect?v=1&tid=UA 482330 7&cid=1955551e 1975 5e52 0cdb 8516071094cd&sc=start&t=pageview&dl=http%3A%2F%2Ftrack.familyfeatures.com%2F18265%2F10675&dt=RADON IS THE SECOND LEADING CAUSE OF LUNG CANCER
track

SOURCE:

Prevent Cancer Foundation

https://stmdailynews.com/beyond-the-piggy-bank-how-to-build-your-childs-financial-future/

Start Your Morning Informed

Get the STM Morning Brief delivered to your inbox every weekday with breaking news, transportation updates, technology, science, and trending stories.

STM News Brief Ad 2

We don’t spam! Read our privacy policy for more info.

Continue Reading

Women's Health

Menopause changes your mouth. Most women have no idea.

Menopause changes your mouth: Many women are familiar with the most talked-about symptoms of menopause – hot flashes, disrupted sleep, brain fog and mood swings. Far fewer know that dry mouth and sensitive teeth belong on that list too.

Published

on

18132 detail intro

Menopause changes your mouth. Most women have no idea.

(Sheeka Sanahori) Many women are familiar with the most talked-about symptoms of menopause – hot flashes, disrupted sleep, brain fog and mood swings. Far fewer know that dry mouth and sensitive teeth belong on that list too.

There’s a name for it: menopause mouth. According to survey data from Delta Dental Insurance Company, 83% of women 40 and older in menopause aren’t aware of any of its symptoms.

18132 detail embed2

What menopause mouth feels like

Forty percent say they have noticed an increase in dry mouth. Another 27% have noticed more tooth sensitivity in recent months, and 26% say things taste different than they used to. You tell yourself it’s something else. You’re not drinking enough water; you’ve been brushing too hard. Menopause isn’t the first thing that comes to mind.

It adds up. Forty-five percent say oral symptoms associated with menopause, such as tooth pain, dry mouth or gum inflammation, take a toll on their confidence, mood or mental health.

18132 detail embed3

Menopause affects the whole body, mentally and physically. So why is the mouth left out?

Even after learning about this connection, 30% of women say they can’t find information about menopause-related oral health concerns. It isn’t that no one is willing to discuss it.

What makes the conversation hard to start

Three-quarters of dentists say they are comfortable discussing menopause with patients. They just want to know who they’re talking to. Most say they would want more patient history, or to know a patient was in menopause, before raising the subject. Forty-five percent say they would not bring up how menopause affects oral health unless a patient asked.

Dentists also believe that patients are already informed. Ninety-four percent say their patients are at least somewhat aware that menopause can affect oral health. So a patient says nothing about her dry mouth, because it doesn’t seem like a dental problem. The dentist doesn’t bring it up either, assuming someone already has.

18132 detail embed4

Women are asking for the information

Nearly nine in 10 women say it would help to receive specific instructions during dental visits about managing oral health during menopause. And 69% say they would be more likely to book an appointment if a primary care provider or OB-GYN had told them menopause affects oral health.

No matter who brings it up, the conversation is one worth having. Hormonal changes during menopause can increase the risk of tooth loss or tooth decay, gum disease, receding gumline or loss of jawbone density. Discussing new oral symptoms with a dentist can help women identify potential problems and address them early.

How to start the conversation with your dentist

Your dentist probably doesn’t know you’re in menopause. Start there.

Questions worth asking:

  • “Could the changes I’m noticing be related to menopause?”
  • “I haven’t had a cavity in 30 years, and now I have two. Could that be tied to hormonal changes?”
  • “What can I do about dry mouth?”
  • “Are there symptoms I should watch for?”
  • “Should I adjust my oral care routine?”

Any one of these questions can get the conversation started.

Methodology

Delta Dental Insurance Company commissioned Atomik Research to conduct two online surveys between June 25 and July 2, 2025.

The first surveyed 200 dentists throughout the United States. The margin of error is +/- 7 percentage points with a 95% confidence level.

Advertisement
Get More From A Face Cleanser And Spa-like Massage

The second surveyed 1,511 women ages 40 or older throughout the United States. To qualify, participants had to indicate they are in perimenopause, menopause or post-menopause. Those who were not sure which stage they were in, or who indicated they were not yet in one of the three stages, were excused from participation. The margin of error is +/- 3 percentage points with a 95% confidence level

Atomik Research, part of 4media group, is an independent market research agency.

Photo courtesy of Shutterstock

collect?v=1&tid=UA 482330 7&cid=1955551e 1975 5e52 0cdb 8516071094cd&sc=start&t=pageview&dl=http%3A%2F%2Ftrack.familyfeatures.com%2F18132%2F10661&dt=MENOPAUSE CHANGES YOUR MOUTH. MOST WOMEN HAVE NO IDEA
track

SOURCE:

Delta Dental Insurance Company

https://stmdailynews.com/beyond-hot-flashes-5-things-women-wish-everyone-knew-about-menopause-2/
Continue Reading

Trending